NASDAQ · HCA
Healthcare · Medical - Care Facilities
$473.19
Down-$4.89 (-1.02%)
Updated Oct 31, 2026, 5:05 PM
SID Score
6.9/10
Composite research score
Smart Money
62/100
Neutral
Price performance · HCA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
HCA closed at $473.19 after 21 trading sessions, up 10.90% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $480.34 | $485.725 | $472.46 | $473.19 | 1.12M |
| Oct 29, 2026 | $469.37 | $478.6575 | $464.92 | $478.08 | 1.26M |
| Oct 28, 2026 | $445.42 | $466.08 | $445.00 | $463.22 | 2.13M |
| Oct 27, 2026 | $480.00 | $488.00 | $439.83 | $449.96 | 2.91M |
| Oct 26, 2026 | $469.54 | $474.49 | $461.39 | $465.26 | 1.88M |
| Oct 23, 2026 | $465.76 | $473.46 | $461.77 | $469.03 | 1.03M |
| Oct 22, 2026 | $460.89 | $467.31 | $456.18 | $467.31 | 872.8K |
| Oct 21, 2026 | $463.73 | $468.045 | $458.38 | $459.40 | 783.11K |
| Oct 20, 2026 | $458.07 | $466.20 | $455.00 | $465.75 | 1.32M |
| Oct 19, 2026 | $453.75 | $460.77 | $453.38 | $454.88 | 918.32K |
| Oct 16, 2026 | $472.15 | $472.49 | $453.94 | $458.84 | 1.73M |
| Oct 15, 2026 | $475.00 | $478.86 | $467.28 | $468.50 | 1.12M |
| Oct 14, 2026 | $463.09 | $472.39 | $457.80 | $470.44 | 1.08M |
| Oct 13, 2026 | $459.54 | $462.44 | $455.81 | $460.75 | 1.08M |
| Oct 12, 2026 | $450.58 | $460.28 | $444.81 | $458.60 | 1.15M |
| Oct 9, 2026 | $444.58 | $452.39 | $442.32 | $451.09 | 981.15K |
| Oct 8, 2026 | $436.95 | $446.48 | $436.00 | $445.01 | 1.13M |
| Oct 7, 2026 | $431.76 | $442.59 | $427.59 | $439.17 | 999.02K |
| Oct 6, 2026 | $433.61 | $438.11 | $429.485 | $432.20 | 999.19K |
| Oct 5, 2026 | $426.70 | $437.27 | $426.00 | $434.92 | 1.15M |
| Oct 2, 2026 | $425.78 | $430.22 | $424.23 | $426.69 | 929.81K |
The latest Smart Investors Daily articles mentioning HCA.
Company
Market Activity
Research & News
HCA research
Company profile and research snapshot.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2024, the firm owned and operated 190 hospitals, 124 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | RBC Capital | Outperform | — |
| Oct 29, 2026 | Barclays | Equal-Weight | — |
| Oct 28, 2026 | TD Cowen | Buy | — |
| Oct 28, 2026 | Keybanc | Overweight | — |
| Oct 28, 2026 | Baird | Neutral | — |
Generated Oct 31, 2026, 5:06 PM
HCA Healthcare (HCA) declined 1.02% today amid a mixed bag of Q3 earnings results and analyst sentiment that reflects both operational challenges and valuation concerns. While the healthcare giant received recognition for clinical excellence and saw RBC maintain an outperform rating, headwinds in surgery volumes and payer mix dynamics are tempering investor enthusiasm across the hospital sector.
Bottom line: HCA Healthcare presents a mixed picture as quality improvements and analyst support from RBC are offset by industry headwinds in surgery volumes and payer mix pressures reflected in Q3 results. Investors should monitor whether management's resiliency initiatives can stabilize volumes and margins while watching for signs of economic weakness that could further depress elective procedure demand; the wide analyst target range ($401-$521) suggests significant uncertainty about fair valuation.
Yahoo · Oct 30, 2026
Hospital operator HCA Healthcare (NYSE:HCA) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 3.6% year on year to $19.85 billion. The company expects the full year’s revenue to be around $78.25 billion, close to analysts’ estimates. Its GAAP profit of $7.27 per share was 7% above analysts’ consensus estimates.
Yahoo · Oct 30, 2026
Defensive stocks are having a moment in the sun.
Benzinga · Oct 30, 2026
RBC Capital analyst Ben Hendrix maintains HCA Healthcare (NYSE:HCA) with a Outperform and raises the price target from $496 to $521.
Yahoo · Oct 30, 2026
ResMed (NYSE:RMD) reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks and residential care software offset declines in life-support device sales. Non-GAAP diluted earning
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HCA.
